⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

September 13, 2024

Figure S3 from Overcoming Osimertinib Resistance with AKT Inhibition in EGFRm-Driven Non–Small Cell Lung Cancer with PIK3CA/PTEN Alterations

Ursula Grazini Aleksandra Markovets Lucy Ireland Daniel O’Neill Benjamin Phillips Man Xu Matthias Pfeifer Tereza Vaclová Matthew J. Martin Ludovic Bigot Luc Friboulet Ryan J. Hartmaier Maria Emanuela Cuomo Simon T. Barry Paul D. Smith Nicolas Floc’h

View at Publisher

Ask AI

Bookmark

Share

Abstract

Figure S3: PC9 PIK3CAm or HCC827 PTENKO cells display diminished osimertinib-mediated apoptotic response that cannot be enhanced by co-treatment with capivasertib.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Grazini et al. (2024) studied this question.

synapsesocial.com/papers/68e58a5ab6db643587526444 https://doi.org/10.1158/1078-0432.27013640

View at Publisher

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Figure S2 from Overcoming Osimertinib Resistance with AKT Inhibition in EGFRm-Driven Non–Small Cell Lung Cancer with PIK3CA/PTEN Alterations2024
2Figure S4 from Overcoming Osimertinib Resistance with AKT Inhibition in EGFRm-Driven Non–Small Cell Lung Cancer with PIK3CA/PTEN Alterations2024
3Table S1 from Overcoming Osimertinib Resistance with AKT Inhibition in EGFRm-Driven Non–Small Cell Lung Cancer with PIK3CA/PTEN Alterations2024
4Table S1 from Overcoming Osimertinib Resistance with AKT Inhibition in EGFRm-Driven Non–Small Cell Lung Cancer with PIK3CA/PTEN Alterations2024
5Figure S1 from Overcoming Osimertinib Resistance with AKT Inhibition in EGFRm-Driven Non–Small Cell Lung Cancer with PIK3CA/PTEN Alterations2024

Data from Overcoming Osimertinib Resistance with AKT Inhibition in EGFRm-Driven Non–Small Cell Lung Cancer with PIK3CA/PTEN Alterations2024
Figure S5 from Overcoming Osimertinib Resistance with AKT Inhibition in EGFRm-Driven Non–Small Cell Lung Cancer with PIK3CA/PTEN Alterations2024
Overcoming Osimertinib Resistance with AKT Inhibition in EGFRm-Driven Non–Small Cell Lung Cancer with PIK3CA/PTEN Alterations2024